Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?

Nat Rev Clin Oncol. 2023 Jul;20(7):423-424. doi: 10.1038/s41571-023-00761-2.
No abstract available

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Humans
  • Immunotherapy
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics